Bcell Design

Bcell Design is a French biotechnology company specializing in the development of innovative mucosal immunotherapy solutions. The company's core expertise lies in its proprietary ARK-IgA platform, which enables the design and production of chimeric IgA antibodies. These antibodies are specifically engineered to target mucosal surfaces, providing a novel approach to treating infectious diseases and certain cancers. Following its acquisition by Innate Pharma in 2016, Bcell Design's technology has been integrated to enhance the development of next-generation antibody-based therapeutics. The company continues to operate as a specialized unit focusing on antibody engineering and mucosal immunity.